Tandem Diabetes Care ( NASDAQ:TNDM – Free Report ) had its price objective reduced by Barclays from $71.00 to $62.00 in a report released on Friday, FlyOnTheWall reports. A number of other research firms have also recently issued reports on TNDM. Bank of America cut Tandem Diabetes Care from a neutral rating to an underperform rating and decreased their target price for the company from $45.00 to $33.00 in a research note on Friday, May 5th. Wells Fargo & Company decreased their target price on Tandem Diabetes Care from $40.

https://www.dailypolitical.com/2023/08/05/tandem-diabetes-care-nasdaqtndm-given-new-62-00-price-target-at-barclays.html

#dailypolitical